New islet transplant trial aims to free type 1 diabetes patients from severe low blood sugar
NCT ID NCT00679042
First seen Apr 07, 2026 · Last updated May 05, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether transplanting insulin-producing cells (islets) from donors can improve blood sugar control in 21 adults with type 1 diabetes who still experience dangerous low blood sugar episodes despite intensive insulin therapy. Participants receive the islet infusion along with lifelong immune-suppressing drugs to prevent rejection. The main goal is to see if patients can achieve a safe blood sugar level (HbA1c ≤ 6.5%) without severe hypoglycemia one year after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Illinois at Chicago Medical Center
Chicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.